Abstract: Alcohol-potentiated antimicrobial soap formulations include an alcohol-potentiated antimicrobial agent ranging from 0.10 to 2.0% (v/v), an alcohol potentiator ranging from 10.0 to 25.0% (v/v), non-ionic surfactants ranging from 0.25 to 5.0% (v/v), an emollient ranging from 0.10 to 3.0% (v/v), solvents ranging from 0.5 to 2.0% (v/v), and a carrier fluid ranging from 70.0 to 90.0% (v/v). Also, alcohol-potentiated hard surface sanitizer formulations include an alcohol-potentiated antimicrobial agent ranging from 0.10 to 1.00% (v/v), 200-proof ethanol ranging from 15.00 to 25.00% (v/v), and water. Also, alcohol-potentiated hard surface disinfectant formulations include a surfactant ranging from 0.50 to 2.00% (v/v), 190 to 200-proof ethanol ranging from 15.00 to 25.00% (v/v), an alcohol-potentiated antimicrobial agent ranging from 0.10 to 2.50, a chelating agent ranging from 0.10 to 1.50% (v/v), and water.

Abstract: A beverage maker according to an embodiment of the present disclosure may comprise: a base; a fermentation module which comprises a fermenter module having an opening part, and a fermentation lid for opening and closing the opening part, and which is disposed on the upper side of the base; a passage module connected to the fermentation module and comprising at least one passage and at least one valve; and a main frame disposed on the upper side of the base and having at least a part of the passage module mounted thereto.

Abstract: An integrated two-phase anaerobic dry fermentation reactor based on a biomimetic principle of rumen includes a reactor body; wherein the reactor body includes a dry fermentation chamber, a secondary fermentation chamber, and a liquid storage chamber. The dry fermentation chamber is arranged at an upper portion of the reactor body. The liquid storage chamber is arranged at a bottom of the reactor body. The secondary fermentation chamber is arranged between the dry fermentation chamber and the liquid storage chamber in the reactor body. The dry fermentation chamber is connected to the secondary fermentation chamber by a porous structure.

Abstract: The present invention provides for methods and at least partially automated devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. Tissue regeneration in humans is extremely limited and constitutes a major challenge to the repair of damaged organ function. Wound treatment is a typical area where tissue regeneration is required. Wounds (lacerations or openings) in mammalian tissue can result in tissue disruption and coagulation of the microvasculature at the wound face.

Abstract: According to one embodiment of the present disclosure, a cell culture system includes: a cell culture container; a liquid storage part configured to store a liquid including a culture medium or a reagent to be supplied to the cell culture container; and a cell collection part configured to collect cells cultured in the cell culture container, wherein the cell culture container, the liquid storage part, and the cell collection part are connected by spatially closed-system lines at least during a period from feeding of the liquid to the cell culture container to removal of the cultured cells, and wherein the cell culture container is arranged in an incubator in a form of a multistage shelf including a liquid supply/discharge port.

Abstract: The present invention relates to a microtissue compartment device, comprising a compartment structure (1) having an upper surface (2) and a lower surface (3) essentially coplanar thereto, and at least two wells (4) suitable for accommodating one or more microtissues (5) in a liquid volume, each well having a lower section (4a) with a given diameter, coaxially oriented thereto an upper section (4b) with an extended diameter, and at least one conduit (6) fluidically connecting at least two wells to one another, and at least one space (13) arranged above a well. At least one well has, in its upper section, a relief structure (9) that prevents spreading or overflow of a liquid volume comprised in said well into space (13).

Abstract: Microfluidic devices, systems, and methods providing for an invasion assay using microfluidic culture systems.

Abstract: The present invention is based in part on the discovery of significant improvements to cell culture systems and methods of generating organoids. The system of the invention provides a novel spinning bioreactor platform for higher-throughput 3D culturing of stem cells (e.g., human induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs)). The system can be widely used as a standard platform to generate stem cell-derived human organoids for any tissue and for high-throughput drug screenings, toxicity testing, and modeling normal human organ development and diseases.

Abstract: A gelled biological growth medium in a culture container, as well as kits and methods of producing the growth medium, utilize gelling of a liquid growth medium containing low methoxyl pectin on a film of calcium salt deposited on a growth surface of the culture container. The salt acts as a trigger for gelation and is conveniently deposited on the walls by evaporation of methanol or another volatile solvent.

Abstract: This disclosure relates to the use of a hydrophobic hollow fiber filter for the filtration of cell cultures and other biological perfusions, due to its resistance to fouling, as well as the ability to filter solutions with a high solid content. A hydrophobic hollow fiber filter may be used within a filter housing in conjunction with a process vessel and a traditional separation system. When the system is used with alternating tangential flow or tangential flow filtration, the hydrophobic hollow fiber filter results in more effective filtration of the filtrate, leading to greater concentration of the retentate, even in solution containing high levels of solids.

Abstract: As a cell-encapsulating device that may supply sufficient oxygen to cells in an implant part and therefore encapsulate a larger cell aggregate, there is provided a cell-encapsulating device comprising a plurality of capsule-form structures arrayed in two-dimensional directions in the same plane, wherein at least a part of outer shells of the capsule-form structures is formed from an oxygen-permeable membrane, and cells are encapsulated in the inside of the capsule-form structures.

Abstract: One aspect relates to a bioreactor and/or mixing container that includes an outer wall and a spectroscopy cell arranged in and/or on the outer wall. The spectroscopy cell includes a first optical area and a second optical area arranged opposite the first optical area. The first optical area and the second optical area can be set at at least two different distances from one another. A specimen-receiving area is located between the first optical area and the second optical area.

Abstract: An automated cell culture and tissue engineering system comprising defined and separate environmental zones provide for increased control and maintenance of the internal environment of the system such that the temperature, air flow and gases surrounding the bioreactor module form one zone that is maintained separately to a second zone formed surrounding the reagent fluid reservoir. The system further comprises means for elimination and/or management of condensation within the second zone of the system.

Abstract: A cell culture device includes a culture unit, a gas supply unit, a first pressure unit, at least one inspecting unit and a control unit. The culture unit contains a cell culture liquid. The gas supply unit, connected with the culture unit, is used for transmitting a culture gas into the culture unit. The first pressure unit, connected with the culture unit, is used for applying a pressure to the cell culture liquid in the culture unit. The at least one inspecting unit, connected with the culture unit, is used for receiving the cell culture liquid for inspection. The control unit, electrically coupled with the culture unit, the first pressure unit, the gas supply unit and the at least one inspecting unit, is used for monitoring corresponding condition parameters to determine respective operations. In addition, a cell culture method for the cell culture device is also provided.

Abstract: The composite biomaterial employs a binding organism (a filamentous fungi that produce mycelium) based on the material physical properties required for the composite biomaterial and a modulating organism (bacteria, fungus or yeast) based on a desired effect of the modulating organism on the binding organism. The modulating organism is selected based on the desired effect on the binding organism.

Abstract: The invention relates to a method for selecting a yeast strain having improved capability for fermenting a pentose, advantageously xylose, in the presence of organic acid, advantageously acetic acid, in non-dissociated form, in which at least one yeast strain that is capable of fermenting said pentose is consecutively cultured in the following two media: a first growth medium comprising said pentose as the only carbon source and said organic acid in non-dissociated form; a second growth medium comprising another carbon source as the only carbon source, advantageously glucose, free of said organic acid in non-dissociated form, the consecutive culture in at least said two growth media being repeated at least twice, in the presence of rising concentrations of organic acid in non-dissociated form.

Abstract: Selective enrichment media and methods for selectively growing and detecting Salmonella spp. and/or Shiga toxin-producing E. coli. The media may comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, nitrofurantoin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. Methods of selectively growing and detecting Salmonella and/or Shiga toxin-producing E. coli are provided.

Abstract: This application provides improved cell culture media and cell culture methods comprising N-acetylcysteine. These improved cell culture media and cell culture methods increase cell viability, cellular growth rate and/or reduce cell doubling time of cholesterol auxotrophic cells, myeloma cells, and hybridoma cells.

Abstract: The present invention provides a culture method of cells and/or tissues including culturing cells and/or tissues in a suspended state by using a medium composition wherein indeterminate structures are formed in a liquid medium, the structures are uniformly dispersed in the solution and substantially retain the cells and/or tissues without substantially increasing the viscosity of the solution, thus affording an effect of preventing sedimentation thereof, and the like

Abstract: A dried tissue model includes a dried hydrogel which is a dried product of a hydrogel composition, in which when a solvent with which the dried hydrogel can be impregnated is used as a second solvent and the dried hydrogel is impregnated with the second solvent to form an impregnated hydrogel, the impregnated hydrogel satisfies at least one of the following: the impregnated hydrogel has a modulus of elasticity in shear of 0.9×102 to 2.1×102 kPa; the impregnated hydrogel has a viscosity of 4.8 to 17.6 kPa; and the ratio of a second Young's modulus at a strain of 0.5 of the impregnated hydrogel to a first Young's modulus at a strain of 0.5 of the hydrogel composition is 0.39 to 0.69.

Abstract: The present invention provides a method for maintaining a continuous epithelial structure of a retinal tissue including culturing the retinal tissue in a medium comprising a methyl group donor or a substrate of the methyl group donor at a concentration at which cell differentiation of a neural retinal progenitor cell is suppressed, and a neurite extension inhibitor at a concentration at which neurite extension is suppressed.

Abstract: The present invention provides a method for freezing a stem cell or a cell derived therefrom, the method including the steps of providing a cell suspension, performing ice nucleation on the cell suspension, and lowering the temperature of the ice nucleated cell suspension to a temperature sufficiently low to allow long term storage of the stem cell. The method is preferably used for the cryopreservation of human embryonic stem cells.

Abstract: The present invention relates to the field of in vitro 3D modeling of neural tissues, particularly of the brain. There is the need of developing cell culture models of neural tissue that reflect physiological aspects of neural tissue. The present invention provides methods of producing bioengineered neuronal organoids (BENOs) which form functional neuronal networks. The present invention also relates to uses and applications of the produced BENOs, e.g., in the fields of drug screening and personalized medicine.

Abstract: Provided is a manufacturing method for a plurality of regenerated hair follicle germs, including a step including simultaneously inoculating a microwell plate including regularly arranged microwell portions with mesenchymal cells and epithelial cells, and co-culturing the mesenchymal cells and the epithelial cells using a medium containing a fibroblast growth factor while supplying oxygen to the mesenchymal cells and the epithelial cells from at least an upper surface and a bottom surface of the microwell plate, to thereby form hair follicle germs in the microwell portions, the microwell plate being formed of a material having oxygen permeability. Also provided is a kit for hair regeneration, including: a microwell plate including regularly arranged microwell portions; and a fibroblast growth factor, wherein the microwell plate is formed of a material having oxygen permeability.

Abstract: The present invention provides a pluripotent stein cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stein cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stein cells. The pluripotent stein cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stein cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.

Abstract: A method is provided for producing a plasmacytoid dendritic cells (pDCs), wherein hematopoietic stem and progenitor cells (HSPCs) are provided and incubated in a first medium comprising cytokines and growth factor whereby the HSPCs are differentiated into precursor-pDCs and then adding interferons (IFNs) to the first medium to obtain a second medium whereby said precursor-pDCs are differentiated into pDCs. Furthermore, a technique is provided for producing genetically modified pDCs, by initially genetically modifying HSPCs using transfection methods, including electroporation, to deliver sgRNA and Cas9 protein Moreover, a pharmaceutical formulation and a vaccine is provided which comprises pDC or genetically modified pDCs obtained according to that method.

Abstract: Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

Abstract: Provided herein are mRNA agent-loaded platelets, methods of preparing mRNA agent-loaded platelets, and methods of using mRNA agent-loaded platelets. In some embodiments, methods of loading mRNA agents into platelets include treating platelets with an mRNA agent, a transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

Abstract: Described here are a genome-edited primary NK cell, methods that includes editing a genome of a primary natural killer (NK) cell, and methods of administering a genome-edited primary NK cell. The primary NK cell may be rested or stimulated.

Abstract: The present invention relates to a method of selecting genetically modified hematopoietic stem cells using the combination of a positive selection marker and a MDR1 inhibitor.

Abstract: Disclosed is a three-dimensional tissue culture, comprising chondrocytes in a biocompatible artificial matrix, having at least the following layers: a first layer located at or close to a surface of the matrix, wherein chondrocytes have a non-spherical shape and are arranged essentially in parallel to the surface along their longest dimension; and a second layer at least partially covered by the first layer wherein the mean sphericity of the chondrocytes of the second layer is higher than the mean sphericity of the chondrocytes of the first layer; and preferably a third layer at least partially covered by the second layer, wherein chondrocytes are arranged into columns extending into the matrix, wherein each column has at least two chondrocytes. Such a tissue culture may for instance be used as artificial cartilage in surgery. Also disclosed is a method to produce such a three-dimensional culture.

Abstract: Described herein are signatures that characterize a particular stromal cell state, type, and/or subtype. In some embodiments, the signatures can characterize a dysfunctional stromal cell. In some embodiments, the signatures can be used to diagnose, treat, and/or prevent a disease. In some embodiments, the signatures can characterize remodeling in a bone marrow microenvironment. Also described herein are cell populations having a specific signature and modulated cells that can be modulate to have a specific signature.

Abstract: Disclosed herein is a method of generating exosomes (extracellular nanovesicles) and/or neo-islets from mesenchymal or adipose stem cells or islets, or other cells in a Hollow-Fiber-based Cell Expansion (HFCE) System. Such exosomes and/or neo-islets may be used for the treatment of T1DM, T2DM, or associated microvascular disease.

Abstract: The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.

Abstract: The present invention refers to a reliable and reproducible industrialisation method for the elimination of air bubbles in the production of an engineered vascular tissue for in vitro testing of medical products for human use and veterinary products for animal use.

Abstract: The present invention discloses a method for establishing a colorectal cancer p73 reporter gene cell line, specifically including: first designing a site-specific sgRNA sequence of a p73 gene and cloning same into a plasmid PX459; integrating a homologous recombination sequence of the p73 gene and a green fluorescent protein DNA fragment (EGFP), and transforming the plasmid and the integrated fragment together into a colorectal cancer cell line HCT116 by electroporation; performing signal cell screening through a flow cytometer to obtain EGFP-expressing cells, and amplifying a monoclonal cell line; and identifying a positive p73 reporter gene cell line through PCR identification and Western blot, among screened EGFP-expressing cell lines. The colorectal cancer cell line p73 gene and the EGFP are co-expressed, and the expression level of the EGFP is highly consistent with that of the p73 gene.

Abstract: The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lig28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring.

Abstract: A medium which contains a riboflavin derivative is useful for proliferating and culturing pluripotent stem cells such as iPS cells and ES cells, and is free from degradation due to storage as complete medium.

Abstract: The present disclosure provides an automated method of producing viral vectors, utilizing engineered viral vector-producing cell lines within a fully-enclosed cell engineering system. Exemplary viral vectors that can be produced include lentivirus vectors, adeno-associated virus vectors, baculovirus vectors and retrovirus vectors.

Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.

Abstract: The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone amine substrate compounds to prepare secondary and tertiary amine product compounds.

Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Abstract: Phototropin is a blue light receptor, which mediates a variety of blue-light elicited physiological processes in plants and algae. In higher plants these processes include phototropism, chloroplast movement and stomatal opening. In the green alga Chlamydomonas reinhardtii, phototropin plays a vital role in progression of the sexual life cycle and in the control of the eye spot size and light sensitivity Phototropin is also involved in blue-light mediated changes in the synthesis of chlorophylls, carotenoids, chlorophyll binding proteins. We compared the transcriptome of phototropin knock out (PHOT KO) mutant and wild-type parent to analyze differences in gene expression in high light grown cultures (500 ?mol photons m?2s?1). Our results indicate the up-regulation of genes involved in photosynthetic electron transport chain, carbon fixation pathway, starch, lipid, and cell cycle control genes.

Abstract: Provided are a group of phi29 DNA polymerase mutants having increased thermal stability and use thereof. The phi29 DNA polymerase mutants are proteins obtained by performing point mutation A and/or point mutation B and/or point mutation C on phi29 DNA polymerase, the point mutation A meaning that an amino acid residue M at position 97 of the phi29 DNA polymerase is mutated to other amino acid residue, the point mutation B meaning that an amino acid residue L at position 123 of the phi29 DNA polymerase is mutated into other amino acid residue, and the point mutation C meaning that an amino acid residue E at position 515 of the phi29 DNA polymerase is mutated to other amino acid residue. The stability of the phi29 DNA polymerase mutants is higher than that of a wild-type phi29 DNA polymerase.

Abstract: The present invention relates to methods of treating or preventing inflammation with a peptide having anti-inflammatory activity, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 101. According to the present invention, the peptide of SEQ ID NO: 101 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the method comprising administration of the peptide of this invention can be used in anti-inflammatory pharmaceutical or cosmetic applications, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: The present invention provides methods and compositions for the treating a patient with one or more conditions associated with PNPLA3 such as nonalcoholic fatty liver disease (NAFLD) nonalcoholic steatohepatitis (NASH), and/or alcoholic liver disease (ALD). Methods and compositions are also provided for modulating the expression of the PNPLA3 gene in a cell by altering gene signaling networks.

Abstract: Certain embodiments are directed to modified or variant Cas9 proteins, and/or methods of using the same.

Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.

Abstract: The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.